

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/591,490	05/10/2007	Takashi Kadowaki	SHIMIZU-13116	1885
7590 02/24/2009 Medlen & Carroll			EXAMINER	
101 Howard Street			NOBLE, MARCIA STEPHENS	
Suite 350 San Francisco.	CA 94105		ART UNIT	PAPER NUMBER
			1632	
			MAIL DATE	DELIVERY MODE
			02/24/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application No. Applicant(s) 10/591,490 KADOWAKI ET AL. Office Action Summary Examiner Art Unit MARCIA S. NOBLE 1632 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1-36 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) _____ is/are allowed. 6) Claim(s) _____ is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-36 are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abevance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No.

Attachment(s)

1) Notice of References Cited (PTO-892)

1) Notice of Draftsperson's Patient Drawing Review (PTO-948)

2) Notice of Draftsperson's Patient Drawing Review (PTO-948)

3) Information. Psed-sure Statem-nt(s) (PTO/SSURE)

Paper No(s)/Mail Date
Paper No(s)/Mail Date
Other:

Other:

Copies of the certified copies of the priority documents have been received in this National Stage

application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Page 2

Application/Control Number: 10/591,490

Art Unit: 1632

DETAILED ACTION

Claims 1-36 are pending.

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to

elect a single invention to which the claims must be restricted.

Group I, claim(s) 18, 19, and 23-28, drawn to a method of removing insulin induced suppression of aponectin receptor (AR) expression by treating cells with a Foxo1 gene.

Group II, claim(s) 18, 20, and 23-28, drawn to a method of removing insulin induced suppression of AR expression by treating cells with a Foxo1 protein.

Group III, claim(s) 18 and 21-28, drawn to a method of removing insulin induced suppression of AR expression by treating cells with an PI3 kinase inhibitor.

Group IV, claim(s) 29-33, drawn to a screening method for a compound that inhibits insulin induced suppression of AR expression.

Group V, claim(s) 34, drawn to a screening method for a compound that reduces PI3 kinase activity.

Group VI, claim(s) 35, drawn to a screening method for a compound that reduces Foxo1 phosphorylation in the presence of Akt.

Group VII, claim(s) 36, drawn to a method of suppressing AR expression by contacting cells with an insulin gene.

Group VIII, claim(s) 36, drawn to a method of suppressing AR expression by contacting cells with an insulin gene.

The inventions listed as Groups I-VIII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Application/Control Number: 10/591,490

Art Unit: 1632

A) The invention has no special technical feature that defined the contribution over the prior art, or

- B) Unity of invention between different categories of inventions will only be found to exist if specific combinations of inventions are present. Those combinations include:
 - 1) A product and a special process of manufacture of said product.
 - 2) A product and a process of use of said product.
- 3) A product, a special process of manufacture of said product, and a process of use of said product.
 - 4) A process and an apparatus specially designed to carry out said process.
- 5) A product, a special process of manufacture of said product, and an apparatus specially designed to carry out said process.

The allowed combinations do not include multiple products, multiple methods of using said products, and methods of making multiple products as claimed in the instant application, see MPEP § 1850 or 37 CFR 1.475.

Applicant's claims encompass multiple inventions and do not have a special technical feature which link the inventions one to the other, and lack unity of invention. The instant claims encompass multiple different method claims. Multiple inventions encompassing multiple different cell treatment methods and multiple different screening methods are not one of the allowed combination of inventions that would be deemed as having unity of invention, as described in situation B. Therefore the instant claims lack unity of invention.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one Application/Control Number: 10/591,490

Art Unit: 1632

or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARCIA S. NOBLE whose telephone number is (571)272-5545. The examiner can normally be reached on M-F 9 to 5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Peter Paras can be reached on (571) 272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Deborah Crouch/ Primary Examiner, Art Unit 1632

Marcia S. Noble AU1632 Application/Control Number: 10/591,490

Page 5

Art Unit: 1632